Rational approach to a conglomerate-forming propranolol derivative: pointed modifications of the crystal structure
暂无分享,去创建一个
[1] G. Coquerel,et al. A Priori Assessment of the Maximum Possible Entrainment Effect Attainable during Preferential Crystallization. The Case of the Simultaneous Resolution of (.+-.)-Ephedrine and (.+-.)-Mandelic Acid , 2004 .
[2] G. Coquerel,et al. How far can an unstable racemic compound affect the performances of preferential crystallization? Example with (R) and (S)-α-methylbenzylamine chloroacetate† , 1998 .
[3] H. Aboul‐Enein,et al. The Impact of Stereochemistry on Drug Development and Use , 1997 .
[4] K. Stoschitzky,et al. Stereoselective Vascular Effects of the (R)- and (S)-Enantiomers of Propranolol and Atenolol , 1995, Journal of cardiovascular pharmacology.
[5] S. Neau,et al. Melting point phase diagrams of free base and hydrochloride salts of bevantolol, pindolol and propranolol , 1993 .
[6] G. H. Dewar,et al. The steric factor in medicinal chemistry , 1993 .
[7] C. Giacovazzo,et al. E‐map improvement in direct procedures , 1991 .
[8] P. Lehmann. Stereoisomerism and drug action , 1986 .
[9] G. M. Goodwin,et al. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5‐HT1 and 5‐HT2 receptors , 1985, British journal of pharmacology.
[10] Jean Jacques,et al. Enantiomers, Racemates, and Resolutions , 1981 .
[11] M. Brienne,et al. Optical resolution by direct crystallization of enantiomer mixtures , 1980 .
[12] H. Ammon,et al. The crystal structures of dichloroisoproterenol, propranolol and propranolol hydrochloride , 1977 .
[13] M. Cotrait,et al. Conformations cristallines d'adrnolytiques -bloquants: propranolol et alprnolol , 1973 .
[14] A. Barrett,et al. The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias , 1968, British journal of pharmacology.
[15] R. Shanks,et al. Optical Isomers of Propranolol , 1966, Nature.